



ANNUAL REPORT

Fiscal Year 2016-2017





A Letter from our Executive Director



It's hard to believe that another year is in the books and a new one is already flying by so fast.

But if you stop and count the impact markers for 2016-17 by the faculty and staff at CBAM, the listing borders on mind-boggling. This year, we numbered 6 faculty, 30 staff. CBAM faculty members received major new support for work in methamphetamine medication research, HIV prevention medication research, and HIV research infrastructure. We have addiction and HIV-focused research underway in the Department of Family Medicine at the UCLA Vine Street Clinic, the UCLA Family Health Center, and the UCLA-Santa Monica Hospital. Our research visits at UCLA Vine Street Clinic this year totaled 2,003—a remarkable new high for our small group.

To accommodate these successes (and reduce the pain from so much activity in such tight quarters), we expanded UCLA Vine Street Clinic, taking over the fourth of five suites in the building. The increased space not only looks beautiful and was completed on time and on budget—it enables our staff to work more comfortably and efficiently as they conduct cutting-edge research.

The clinical endeavor continues to broaden as our faculty lead efforts to provide addiction medicine services at UCLA. This includes a fast-growing clinical service with five senior faculty involved. The services provided range from treating pain in the setting of addiction, to outpatient addiction medicine, to evaluation and care for patients with complex workplace injuries, to psychiatric and behavioral medicine. CBAM faculty even provide addiction screening and brief intervention services to the UCLA Athletics Department, serving student athletes on campus in order to maximize access to needed services.

I'm proud of all of us. I'm proud not only of our accomplishments as a group of researchers in one of the nation's leading Departments of Family Medicine. I'm grateful for our capacity to draw on strengths of each other as we lead different, but related disciplines to ensure ever-innovative, high-impact protocols in outstanding team science. I'm also proud of the way we do the work. No matter what the next year brings, I know we are in outstanding shape for leading science and treatment and for bringing the voice of our communities into our work.



About CBAM

CBAM is a multidisciplinary center that seeks to advance the prevention and treatment of chronic illness, especially in communities with health disparities.

As part of the UCLA Department of Family Medicine, CBAM works at the intersection of academia and community with a focus on treating addictions and preventing the spread of HIV.

Highlights



2,003 Research Visits (a 16% increase from the previous year)



3,249 Outpatient Visits for Behavioral Therapy and Medication-Assisted Treatment for Addiction



More than \$6million in funding for research, training and clinical services



36 Full and Part-Time Employees on our team



26 Peer-reviewed Manuscripts Published



1,108 people attended meetings/trainings sponsored or co-sponsored by CBAM



818 HIV tests performed as part of research visits



2,790 STI tests performed as part of research visits with 103 positive results (approximately 4%)



Research Highlights

This year, we reached an auspicious milestone: Dr. Shoptaw, Dr. Landovitz and Uyen Kao successfully re-competed the UCLA Center for HIV Identification, Prevention and Treatment Services (CHIPTS). This achievement ensures an additional five years of infrastructure support and continues nearly 20 years of work by Dr. Mary Jane Rotheram-Borus in generating high-impact HIV prevention research domestically and globally. The theme for this renewal focuses on research addressing comorbidities of mental health and substance use disorders in order to reduce the number of new HIV infections and to increase rates of viral suppression among people living with HIV. CHIPTS continues to foster collaboration among institutions throughout Los Angeles, including Friends Research Institute, Charles R. Drew University, RAND, and LA County Department of Public Health. CHIPTS has a world-class scientific advisory board, an energetic community advisory board, and an innovative, mentored pilot grant program. Our dissemination activities are carried out both locally and internationally. We are thrilled with this achievement and look forward to carrying on the tradition of outstanding research started by Dr. Rotheram.



In the spring, we launched a new clinical trial as part of NIDA's Clinical Trial Network effort to find a medication for the treatment of methamphetamine dependence. The ADAPT-2 study (Accelerated Development of Additive Pharmacotherapy Treatment) is a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy of extended-release naltrexone plus bupropion as a combination pharmacotherapy. Participants will be randomly assigned to the active medication combination group or matching placebo group and will receive medications over the course of 12 weeks. Our research team at the UCLA Family Health Center, pictured to the left, has more than 80 years combined experience in the field.


CBAM and the UCLA Vine Street Clinic (UVSC) were well-represented this year at the 2017 HIV Prevention Trials Network annual meeting. Our site continues to enroll participants into the AMP Study and this year we launched HPTN 083 (led by Dr. Raphael Landovitz), which compares daily Truvada to a long-lasting injectable medication for HIV prevention. UVSC HIV prevention research is overseen by our new Medical Director, Dr. Jesse Clark. In addition, our Community Engagement and Outreach Team, led by Christopher Blades, disseminates findings from our studies to community advisory board members, community based organizations and service providers in key locations across L.A. Go team Vine Street!





Research Highlights (continued)

Dr. Ron Brooks launched the LA PrEP Stories Project this year. The goal of this study is to learn about the experiences of Black and Latino men who sex with men (BLMSM) who are using Pre-Exposure Prophylaxis (PrEP) for HIV prevention and to assess its impact on PrEP disclosure, adherence and retention, and dissemination of PrEP information to other potential PrEP consumers. Interviews were also held with BLMSM non-PrEP adopters to assess their reasons for not seeking out PrEP. This study is funded by the National Institute of Mental Health and additional support was received from the California Community Foundation to expand the project to include Black and Latina trans women who have sex with men. With this information, we seek to mitigate any of the negative social experiences that may arise from a person's use of PrEP.




Despite multiple clinical trials testing medications that target dopaminergic, serotonergic, cholinergic, and gaba-ergic systems, no effective medication for methamphetamine (MA) use disorder is currently available. In addition to our on-going Phase II clinical trials, Dr. Keith Heinzerling has launched a Phase I study to assess the safety of a medication called pomaglometad methionil (or POMA for short) as a potential, future treatment option. This inpatient study is being conducted at the UCLA Medical Center in Santa Monica. It includes a brief, outpatient screening period, a 10-night stay in the hospital and an outpatient follow up visits.



Publications



CBAM faculty and staff contributed to the publication of 26 peer-reviewed articles in scientific journals ranging from the *Journal of Clinical Psychopharmacology* to *AIDS* to *Addiction*. This includes the first in what promises to be a long series of papers from data on our cohort study, the mSTUDY! The paper, entitled [Correlates of Preexposure Prophylaxis \(PrEP\) Use among Men Who Have Sex with Men \(MSM\) in Los Angeles, California](https://link.springer.com/article/10.1007%2Fs11524-017-0172-z) looks at socio-structural and behavioral factors in 185 high-risk, HIV-negative, minority men who have sex with men. Our findings, published in the *Journal of Urban Health* in June, provide important considerations for the development of interventions to promote the use of PrEP among this key population. Read more here: <https://link.springer.com/article/10.1007%2Fs11524-017-0172-z>.





UCLA Vine Street Clinic

This was our most exciting and productive year yet at the UCLA Vine Street Clinic (UVSC). We underwent a significant expansion, increasing our space by more than 1,200 square feet to a total of 3,650. To the right you can see our new space before installation of staff cubicles. Moving us into this newly renovated area allowed us to convert two offices into patient care areas including a new exam room! Our lobby also got a significant redesign. With the help of BC Studio LA, interior designers, and Rob Reilly Painting we



were able to transform the space from what you see above in the lower left corner, to the more welcoming space pictured at the lower right. This expansion came not a minute too soon as we continued to increase our productivity, exceeding a total of 2,000 patient visits this year! While some visits are as quick as 20 minutes, many can take up to 2-3 hours, so this is a significant volume for our little clinic. We thank our incredible staff for their hard work which makes all of this possible.

Training

CBAM's training activities seek to inspire the next generation of clinicians, researchers, and public health professionals to use evidence-based interventions that have been proven to work. This year,




CBAMer Keith Heinzerling, MD joined other addiction medicine doctors and the Center for Care Innovations as part of the "Treating Addiction in the Primary Care Safety Net Program" (TAPC), which seeks to increase access to medication-assisted treatment (MAT) for Californians facing opiate addiction. Dr. Heinzerling provides support and guidance to participating community health centers on how to choose and implement the best MAT models for their site. He provides technical assistance to clinicians and advises on way to strengthen workplace culture in order to support addiction treatment.

We continue to host an intern from the NIDA's Summer Research Program for underrepresented undergraduate students. CBAM has been participating in this program for nearly a decade. This year's student, India Harper, came to us from Morgan State University in Baltimore, MD. She spent the summer researching pharmacotherapies for alcohol dependence in disparity clinics. India's future career goal is to become a clinical psychologist and to work with minority populations with mental illness. Our Medical Director at the UCLA Vine Street Clinic, Dr. Clark, also mentored a student and a medical resident this year, Stephanie Clavijo. As part of the mentorship, Drs. Clark and Shoptaw helped Stephanie prepare a poster for a poster fair, attended by members of the UCLA community.



Our Patients

We are so thankful for our patients. Whether they come to us for clinical services or to participate in a research study, we take their care seriously and work hard to enhance their well being. We are especially touched when our patients thank us back! This lovely card arrived at the UCLA Vine Street Clinic over the holidays. It came from a patient who screened for one of our methamphetamine clinical trials. She was ultimately considered ineligible because of a medical condition we diagnosed during screening, but that diagnosis prompted her to see her primary care physician. She wrote to let us know that, not only is her condition now under control, but that “My visits to your clinic were the catalyst that inspired my abstinence”. At the time she wrote this, she had been clean for more than a month.



Clinical Services

CBAM also has a presence at the UCLA Family Health Center (UFHC) in Santa Monica. This is the main practice site for our Department whose leadership has continued to support strong programs to address addiction and behavioral health. At UFHC, patients have access to addiction specialists, Dr. Keith Heinzerling & Dr. Joy Hao, a psychologist, Dr. Joy Chudzynski, and a psychiatrist, Dr. Timothy Hall. Dr. Chudzynski provides short-term cognitive behavioral therapy (CBT) to patients established at the site, as well as consults to the addiction medicine and psychiatry providers. Dr. Hall is the on-site psychiatrist for UFHC patients, while also teaching the residents about psychiatric treatment in the primary care setting.



Drs. Heinzerling and Hao accept referrals from all UCLA offices and outside of the UCLA system. Along with treating patients for alcohol use and drug use, the addiction medicine program has steadily grown as patients are referred for evaluation of opioid dependence and opioid tapers. Many patients have been on high dose opioids for several years for chronic pain or have recently been prescribed opiates following a surgery or injury and come to us as a preemptive measure. After working with the addiction specialists, many patients are able to find non-narcotic relief for their chronic pain, with the use of alternate medications, physical and occupational therapy, and behavioral support. These complementary treatments help patients cope with their pain, while also increasing their quality of life, decreasing the amount of medications they take, and limiting visits to the emergency room. By providing specialty services within the primary care setting, patients are able to seek out and receive the treatment they need without the stigma that comes with some outpatient addiction and behavioral programs. The CBAM programs at UFHC strive to provide support to an underserved population in a nonjudgmental setting, while also delivering the high level of care for which UCLA is known.



International Reach

Our work continued this year with the University of Cape Town (UCT) through collaboration on a project comparing fMRI images from 30 methamphetamine-dependent individuals using a high-value contingency management (CM) program. The goal of this project is to describe the neurobiological mechanisms of action underpinning CM. The study surpassed its half-way point and we will be preparing to analyze data and begin writing papers over the coming year. We also increased our mentorship activities, hosting UCT faculty member, Dr. Jonathan Ipser who gave a presentation to UCLA faculty and staff on Development of a Gait-Based Mobile Health Screen for Neurodevelopmental Delay in Adolescents with HIV and worked closely with our faculty on development of a new grant.




Dr. Shoptaw traveled to Vietnam this year where he attended the Amphetamine-Type Stimulants (ATS) Workshop. There he presented on “The Use of ATS and the Risk of HIV Infection in the United States: Some Models of Intervention.”

Pictured here is Dr. Shoptaw (right) with Professor Robert Ali (left) from Australia and Professor Apinum Aramrattana (center) from Thailand.

This initial visit produced opportunities for joint research activities with researchers from Hanoi Medical University (HMU) and other scholars. This upcoming year, Dr. Diep from HMU will be attending UCLA School of Public Health to receive advanced training in methamphetamine medication trials with our group at the UCLA Vine Street Clinic.

Dr. Shoptaw was invited for his first visit to CROI to lead a panel discussion on emerging substance-related, HIV transmission findings. CROI is the annual Conference on Retroviruses and Opportunistic Infections, which was held this year in Seattle. As noted on their website, CROI brings together top basic, translational, and clinical researchers from around the world to share the latest studies, important developments, and best research methods in the ongoing battle against HIV/AIDS and related infectious diseases. Five scientists presented data on stimulant risks including emerging methamphetamine use in African American MSM and new injection drug use risks in Seattle.





CENTER FOR BEHAVIORAL & ADDICTION MEDICINE
Financial Statement for Fiscal Year 2016/2017
(July 1, 2016 through June 30, 2017)

INCOME	Permanently Restricted	Temporarily Restricted	Unrestricted	Total	FY 2015/2016
Federal Contracts & Grants	\$ 5,352,889	\$ -	\$ -	\$ 5,352,889	\$ 3,863,520
State/Local Contracts & Grants	\$ -	\$ -	\$ -	\$ -	\$ -
Subcontracts	\$ 193,514	\$ -	\$ -	\$ 193,514	\$ 201,871
Corporations	\$ -	\$ -	\$ -	\$ -	\$ -
Foundations	\$ -	\$ -	\$ -	\$ -	\$ -
Individuals	\$ -	\$ -	\$ -	\$ -	\$ -
UC Funds	\$ -	\$ -	\$ 132,647	\$ 132,647	\$ 249,811
Clinical Services Income	\$ -	\$ 659,234	\$ -	\$ 659,234	\$ 609,388
TOTAL INCOME	\$ 5,546,403	\$ 659,234	\$ 132,647	\$ 6,338,284	\$ 4,924,590
EXPENSES					
Academic Salaries				\$ 695,775	\$ 880,915
Staff Salaries				\$ 1,271,681	\$ 1,026,421
Fringe Benefits				\$ 828,404	\$ 752,582
Stipends - Postdoctoral Fellows				\$ -	\$ 3,640
Stipends - Interns				\$ 5,780	\$ 9,355
Consultants/Guest Lecturers				\$ 42,045	\$ 17,862
Tuition - Postdoctoral Fellows				\$ -	\$ -
Employee Training/Certifications/Licenses/Memberships				\$ 2,308	\$ 990
Subawards				\$ 64,226	\$ 32,062
Space Rental				\$ 170,729	\$ 150,237
Alterations/Renovations				\$ 72,198	\$ -
Communications				\$ 37,487	\$ 35,535
Clinic Operations				\$ 35,270	\$ 27,912
General Supplies & Equipment				\$ 3,759	\$ 1,130
Computers, Software & Computer Supplies				\$ 32,643	\$ 16,326
Medical Supplies				\$ 48,530	\$ 59,562
Project-Related Supplies				\$ 31,865	\$ 26,547
Travel and Events				\$ 110,277	\$ 99,441
Postage/Courier				\$ 19,805	\$ 8,503
Print/Copy Services				\$ 835	\$ 4,634
Recruitment Ads				\$ 75,569	\$ 60,459
Lab Services				\$ 68,519	\$ 68,826
Pharmacy				\$ 45,070	\$ 9,658
Participant Incentives				\$ 103,910	\$ 61,731
Miscellaneous				\$ 5,611	\$ 7,630
Indirect Charges				\$ 745,442	\$ 604,044
TOTAL EXPENSES				\$ 4,517,738	\$ 3,966,002
NET INCOME (LOSS) YTD*				\$ 1,820,546	\$ 958,588


*This document was generated internally. It is not an audited financial statement.
 The net balance is restricted project funding that will carryover into the next fiscal year.



Make a Donation

CBAM is unique in that we bring research directly into the communities we serve. Help us to serve more by donating today!

Visit us at <http://www.uclacbam.org/about-us/donate/> or call (310) 794-0619 ext. 229 to speak with our Administrative Director. More than 90% of the money you give will go directly to serve our mission and all donations are tax deductible. Naming opportunities are available!



Contact Us!

UCLA Center for Behavioral &
Addiction Medicine
10880 Wilshire Blvd., Ste. 1800
Los Angeles, CA 90024
(310) 794-0619
cbam@mednet.ucla.edu
cbam.ucla.edu